HONG KONG – Irvine, Calif.-based Trigr Therapeutics Inc. has signed an exclusive licensing deal with Shanghai-based Elpiscience Biopharmaceuticals Co. Ltd., known as Kewang in China. The two companies will develop and commercialize TR-009 in mainland China, Hong Kong, Macau and Taiwan.